CERS Stock Analysis: Cerus | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 633m USD | 12M Return: 101.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.88M
Qual. Beats: 1
Rev. Trend: 99.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cerus Corporation is a U.S.-based biomedical products company headquartered in Concord, California, specializing in blood safety through its proprietary INTERCEPT Blood System platform. The technology uses a controlled biological replication process to inactivate a broad spectrum of blood-borne pathogens in donated platelets, plasma, and red blood cells intended for transfusion, as well as in pathogen-reduced cryoprecipitate used to treat bleeding associated with fibrinogen deficiency. The system also includes the INTERCEPT Illuminator, an LED-based device used to treat blood components.
The company distributes its platelet and plasma systems through both a direct sales force and third-party distributors, with commercial reach spanning the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and other international markets. Founded in 1991 and renamed Cerus Corporation in 1996, the company trades on NASDAQ under the ticker CERS and is classified within the GICS Health Care Supplies sub-industry, a segment that includes specialized medical device and consumables makers serving transfusion medicine, hospital, and clinical laboratory customers.
- INTERCEPT platelet and plasma sales drive quarterly revenue growth
- Red blood cell system FDA approval expands addressable market
- European hospital adoption accelerates pathogen reduction demand
| Net Income: -9.55m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -3.79 > 1.0 |
| NWC/Revenue: 30.50% < 20% (prev 49.60%; Δ -19.09% < -1%) |
| CFO/TA 0.01 > 3% & CFO 2.63m > Net Income -9.55m |
| Net Debt (29.5m) to EBITDA (1.19m): 24.76 < 3 |
| Current Ratio: 1.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (194.1m) vs 12m ago 3.78% < -2% |
| Gross Margin: 54.31% > 18% (prev 56.00%; Δ -1.69% > 0.5%) |
| Asset Turnover: 103.7% > 50% (prev 89.54%; Δ 14.16% > 0%) |
| Interest Coverage Ratio: -0.13 > 6 (EBIT TTM -1.09m / Interest Expense TTM 8.11m) |
| A: 0.30 (Total Current Assets 175.3m - Total Current Liabilities 107.4m) / Total Assets 222.9m |
| B: -4.86 (Retained Earnings -1.08b / Total Assets 222.9m) |
| C: -0.01 (EBIT TTM -1.09m / Avg Total Assets 214.8m) |
| D: 0.44 (Book Value of Equity 67.6m / Total Liabilities 154.6m) |
| Altman-Z'' = -13.41 = D |
| DSRI: 0.92 (Receivables 29.3m/26.3m, Revenue 222.8m/185.1m) |
| GMI: 1.03 (GM 56.00% / 54.31%) |
| AQI: 0.92 (AQ_t 0.13 / AQ_t-1 0.14) |
| SGI: 1.20 (Revenue 222.8m / 185.1m) |
| TATA: -0.05 (NI -9.55m - CFO 2.63m) / TA 222.9m) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 3.12 with a total of 1,717,000 shares traded. Over the past week, the price has changed by -1.27%, over one month by +21.87%, over three months by +65.08% and over the past year by +101.29%.
Current recommended Stop Loss: 2.60 (which is 16.7% or 2.7 ATR below the current price).
Cerus has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy CERS.
- StrongBuy: 4
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.7 | 49.7% |
P/S = 2.9238
P/B = 9.4025
Revenue TTM = 222.8m USD
EBIT TTM = -1.09m USD
EBITDA TTM = 1.19m USD
Long Term Debt = 32.4m USD (from longTermDebt, last quarter)
Short Term Debt = 55.5m USD (from shortTermDebt, last quarter)
Debt = 109.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.5m
Net Debt = 29.5m USD (calculated: Debt 109.9m - CCE 80.4m)
Enterprise Value = 662.6m USD (633.2m + Debt 109.9m - CCE 80.4m)
Interest Coverage Ratio = -0.13 (Ebit TTM -1.09m / Interest Expense TTM 8.11m)
EV/FCF = -544.0x (Enterprise Value 662.6m / FCF TTM -1.22m)
FCF Yield = -0.18% (FCF TTM -1.22m / Enterprise Value 662.6m)
FCF Margin = -0.55% (FCF TTM -1.22m / Revenue TTM 222.8m)
Net Margin = -4.29% (Net Income TTM -9.55m / Revenue TTM 222.8m)
Gross Margin = 54.31% ((Revenue TTM 222.8m - Cost of Revenue TTM 101.8m) / Revenue TTM)
Gross Margin QoQ = 56.98% (prev 51.51%)
Tobins Q-Ratio = 2.97 (Enterprise Value 662.6m / Total Assets 222.9m)
Interest Expense / Debt = 7.38% (Interest Expense 8.11m / Debt 109.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -862k (EBIT -1.09m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.63 (Total Current Assets 175.3m / Total Current Liabilities 107.4m)
Debt / Equity = 1.63 (Debt 109.9m / totalStockholderEquity, last quarter 67.6m)
Debt / EBITDA = 24.76 (Net Debt 29.5m / EBITDA 1.19m)
Debt / FCF = -24.19 (negative FCF - burning cash) (Net Debt 29.5m / FCF TTM -1.22m)
Total Stockholder Equity = 62.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.45% (Net Income -9.55m / Total Assets 222.9m)
RoE = -15.36% (Net Income TTM -9.55m / Total Stockholder Equity 62.2m)
RoCE = -1.15% (EBIT -1.09m / Capital Employed (Equity 62.2m + L.T.Debt 32.4m))
RoIC = -0.54% (negative operating profit) (NOPAT -862k / Invested Capital 159.9m)
WACC = 10.34% (E(633.2m)/V(743.1m) * Re(11.12%) + D(109.9m)/V(743.1m) * Rd(7.38%) * (1-Tc(0.21)))
Discount Rate = 11.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 3.11%
[DCF] Fair Price = unknown (Cash Flow -1.22m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.79 | # QB: 1
Revenue Correlation: 99.03 | Revenue CAGR: 14.26% | SUE: 1.82 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.01 | Chg30d=N/A | Revisions=-25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.01 | Chg30d=N/A | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.03 | Chg30d=+50.00% | Revisions=-40% | GrowthEPS=+62.5% | GrowthRev=+15.5%
EPS next Year (2027-12-31): EPS=0.00 | Chg30d=N/A | Revisions=-25% | GrowthEPS=+100.0% | GrowthRev=+9.1%
[Analyst] Revisions Ratio: -62% (up=0, down=5)